Arax Advisory Partners’s Grace Therapeutics GRCE Stock Holding History

Arax Advisory Partners’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.27K	Buy	1,000 +500	+100%	+$1.38K	﹤0.01%	4786
2026 Q1	$2.31K	Buy	+500	New	+$1.96K	﹤0.01%	3070

Other funds holding GRCE

Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Arax Advisory Partners's GRCE Position: Q2 2026 in Review

Arax Advisory Partners increased its Grace Therapeutics (GRCE) stake by 100% in Q2 2026, buying an estimated $1.38K and bringing the position to 1,000 shares worth $2.27K. The position accounts for ﹤0.01% of the portfolio, ranked #4786.

Arax Advisory Partners first reported a position in GRCE in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.31K in Q1 2026. 33 funds tracked by Wall St. Rank hold GRCE as of Q2 2026.

Arax Advisory Partners held 1,000 shares of Grace Therapeutics worth $2.27K as of Q2 2026.
Arax Advisory Partners bought 500 Grace Therapeutics shares in Q2 2026, an estimated $1.38K.
Grace Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4786 holding.
Arax Advisory Partners first reported a position in Grace Therapeutics in Q1 2026 and has held it in 2 quarters since.
Arax Advisory Partners's Grace Therapeutics position peaked at $2.31K in Q1 2026.
33 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.